Oral Solid Dosage Contract Manufacturing Global Market 2024 - By Share, Growth, Demand, Trends, Forecast To 2033
Global oral solid dosage contract manufacturing market size is expected to reach $52.94 Bn by 2028 at a rate of 7.3%, segmented as by product type, tablets, capsules, powders, granules, other product types
Varun Pathuri Share this Post to earn Money ( Upto ₹100 per 1000 Views )
The oral solid dosage contract manufacturing market size is expected to see strong growth in the next few years. It will grow to $52.94 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to increasing outsourcing by pharmaceutical companies, advancements in drug delivery technology, and increasing drug development activities. Major trends in the forecast period include advancements in drug delivery technology, integration of 3D printing, and advancements in controlled-release technologies.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/oral-solid-dosage-contract-manufacturing-global-market-report
Scope Of Oral Solid Dosage Contract Manufacturing Market
The Business Research Company's reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Oral Solid Dosage Contract Manufacturing Market Overview
Market Drivers -
The increase in demand for generic drugs is expected to propel the growth of the oral solid dosage contract manufacturing market going forward. Generic drugs are medications that are bioequivalent to brand-name drugs in dosage, strength, safety, performance, quality, and intended use. The rising demand for generic drugs is attributed to patent expirations, cost containment efforts, regulatory incentives, and expanding access to healthcare. Oral solid dosage contract manufacturing significantly aids the production and distribution of generic drugs by leveraging the capabilities of contract manufacturers to enhance their operational efficiency, reduce costs, ensure high-quality production, and bring their products to market more swiftly and effectively. For instance, in 2022, according to the Food and Drug Administration, a US-based federal agency, it is estimated that 91% of all prescriptions in the USA were filled with generic drugs, with more than 32,000 generic drugs approved by the FDA (Food and Drug Administration). Therefore, the demand for generic drugs drives the growth of the oral solid dosage contract manufacturing market.
Market Trends -
Major companies operating in the oral solid dosage contract manufacturing market are focused on developing innovative solutions, such as continuous manufacturing lines, to sustain their position in the market. A continuous manufacturing line refers to a production facility or system that utilizes continuous manufacturing processes to produce pharmaceuticals or other products. For instance, in January 2023, WuXi STA, a China-based pharmaceutical company, launched its first continuous manufacturing line for oral solid pharmaceutical products. This cutting-edge facility marks a significant advancement in pharmaceutical production, leveraging continuous manufacturing principles to enhance efficiency, quality, and flexibility in drug manufacturing processes. This agility streamlines production timelines and reduces downtime, ultimately accelerating the delivery of vital medications to patients.
The oral solid dosage contract manufacturing market covered in this report is segmented –
1) By Product Type: Tablets, Capsules, Powders, Granules, Other Product Types
2) By Service: Drug Product Development, Fill Finish Product Manufacturing, API Manufacturing, Packaging And Labelling, Other Applications
3) By Therapeutic Area: Oncology, Cardiovascular Diseases, Metabolic Disorders, Neurological Disorders, infectious Diseases, Gastrointestinal Diseases, Other Therapeutic Areas
4) By End User: Large Size Companies, Medium And Small Size Companies
Get an inside scoop of the oral solid dosage contract manufacturing market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=16137&type=smp
Regional Insights -
Asia Pacific was the largest region in the oral solid dosage contract manufacturing market in 2023. The regions covered in the oral solid dosage contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies -
Major companies operating in the oral solid dosage contract manufacturing market are Pfizer Inc., Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Merck KGaA, Siemens Healthineers AG, Evonik Industries AG, Teva Pharmaceutical Industries Ltd., Lonza Group AG, Catalent Inc., Patheon Pharma Services, Fareva Holding SA, Piramal Enterprises Limited, Hetero Drugs Limited, Siegfried Holding AG, Recipharm AB, Almac Group Limited, Aenova Holding GmbH, Jubilant Pharmova Limited, Cambrex Corporation, International Chemical Investors Group (ICIG) operates under the CordenPharma brand, Ajinomoto Co. Inc., Hovione Holding Ltd., Alcami Corporation
Table of Contents
1. Executive Summary
2. Oral Solid Dosage Contract Manufacturing Market Report Structure
3. Oral Solid Dosage Contract Manufacturing Market Trends And Strategies
4. Oral Solid Dosage Contract Manufacturing Market – Macro Economic Scenario
5. Oral Solid Dosage Contract Manufacturing Market Size And Growth
…..
27. Oral Solid Dosage Contract Manufacturing Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
